Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/8/2019
SIETES contiene 92794 citas

 
 
 1 a 15 de 15 
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Marciniak TA, Cherepanov V, Golukhova I, Hyun Kim M, Serebruany V. Drug discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern Med 2016;176:11 de enero. [Ref.ID 99961]
2. Cita con resumen
Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007;147:590-1. [Ref.ID 81292]
3.Tiene citas relacionadas Cita con resumen
Garcia D, Hylek E. Stroke prevention in elderly patients with atrial fibrillation. Lancet 2007;370:460-1. [Ref.ID 80879]
4.Tiene citas relacionadas
White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Results from SPORTIF III and V. Arch Intern Med 2007;167:239-45. [Ref.ID 79193]
5. Cita con resumen
Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med 2006;145:62-9. [Ref.ID 77577]
6.Tiene citas relacionadas Cita con resumen
Verheugt FWA. Good old warfarin for stroke prevention in atrial fibrillation. Lancet 2006;367:1877-8. [Ref.ID 77184]
7.
Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40. [Ref.ID 74757]
8.Tiene citas relacionadas Cita con resumen
Gurewich V. Ximelagatran - promises and concerns. JAMA 2005;293:736-9. [Ref.ID 72740]
9.Tiene citas relacionadas Cita con resumen
O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706. [Ref.ID 72739]
10.Tiene citas relacionadas Cita con resumen
SPORTIF Executive steering committee for the SPORTIF V investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. A randomized trial. JAMA 2005;293:690-8. [Ref.ID 72738]
11.Tiene citas relacionadas Cita con resumen
Fiessinger JN, Huisman MV, Davidson BL, Bounameux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS, for the THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial. JAMA 2005;293:681-9. [Ref.ID 72737]
12.Tiene citas relacionadas Cita con resumen
Olsson SB, for the SPORTIF Executive Steering Committee. Ximelagatran or warfarin in atrial fibrillation? Authors' reply. Lancet 2004;363:736. [Ref.ID 69305]
13.Tiene citas relacionadas Cita con resumen
Verheugt FWA. Ximelagatran or warfarin in atrial fibrillation? Commentator's reply. Lancet 2004;363:734. [Ref.ID 69301]
14.Tiene citas relacionadas Cita con resumen
Eikelboom J, Hankey G. Ximelagatran or warfarin in atrial fibrillation?. Lancet 2004;363:734. [Ref.ID 69300]
15.Tiene citas relacionadas Cita con resumen
Verheught FWA. Can we pull the plug on warfarin in atrial fibrillation?. Lancet 2003;362:1686-7. [Ref.ID 68203]
Seleccionar todas
 
 1 a 15 de 15